Inhaled Nitric Oxide Market Report Scope & Overview:

The Inhaled Nitric Oxide Market size is valued at USD 1.02 Billion in 2025 and is projected to reach USD 2.01 Billion by 2035, growing at a CAGR of 7.15% during the forecast period 2026–2035.

The Inhaled Nitric Oxide Market analysis report examines the current trends in market dynamics, technology innovations in delivery systems, and increased medical uses for the treatment modality. The high prevalence of newborn hypoxia-induced respiratory disorders, increasing cases of pulmonary hypertension and ARDS, improved nitric oxide delivery systems, and improved critical care facilities will fuel sustained market growth from 2026 to 2035.

Inhaled nitric oxide therapy treatments surpassed 1.5 million doses in 2025, owing to increased NICU admissions, enhanced respiratory treatment capabilities, and increased use in new healthcare markets.

Market Size and Forecast:

• Market Size in 2025: USD 1.02 Billion

• Market Size by 2035: USD 2.01 Billion

• CAGR: 7.15% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

Inhaled Nitric Oxide Market Trends:

• Increasing incidence of neonatal hypoxic respiratory failure (NHRF) and pulmonary hypertension is driving demand for inhaled nitric oxide therapy in critical care settings.

• Rising prevalence of acute respiratory distress syndrome (ARDS) and other respiratory conditions is expanding the clinical use of inhaled nitric oxide beyond neonatal care.

• Advancements in portable and tankless nitric oxide delivery systems are improving accessibility, flexibility, and ease of administration.

• Integration of inhaled nitric oxide delivery with ventilators and monitoring systems is enhancing treatment precision and patient safety.

• Growing expansion of neonatal intensive care units (NICUs), hospitals, and critical care infrastructure is supporting wider adoption of iNO therapy.

• Increasing focus on home-based and ambulatory respiratory care is enabling gradual adoption of portable nitric oxide delivery solutions.

• Ongoing clinical research and trials for new indications are broadening the therapeutic scope of inhaled nitric oxide.

• Strategic collaborations between medical gas providers, device manufacturers, and healthcare institutions are accelerating innovation and market expansion.

U.S. Inhaled Nitric Oxide Market Insights:

U.S. Inhaled Nitric Oxide Market Size Forecasted to reach USD 0.71 Billion by 2035 growing at a CAGR of 6.47%, from USD 0.38 Billion in 2025. The growing incidence rate of hypoxic respiratory failure among newborns, growing number of patients with pulmonary hypertension and ARDS, high adoption rates of advanced nitric oxide inhalation systems, and continuous investments in NICUs are some key factors that will boost market growth.

Inhaled Nitric Oxide Market Growth Drivers:

• Rising incidence of neonatal respiratory disorders and pulmonary hypertension driving demand for inhaled nitric oxide therapy.

Growing incidences of hypoxia and ARDS among infants, and increased prevalence of pulmonary hypertension, are important factors influencing the Inhaled Nitric Oxide Market. Increased adoption of inhaled nitric oxide treatments by hospitals and neonatal intensive care units (NICUs) for treating patients suffering from critical breathing problems is driving the market. Innovation in inhaled nitric oxide delivery devices and their growing efficacy in delivering effective treatments at lower costs are further fueling adoption rates and expanding the market.

In 2025, more than 62% of hospitals and NICUs were using inhaled nitric oxide treatments.

Inhaled Nitric Oxide Market Restraints:

• High cost of inhaled nitric oxide therapy and infrastructure requirements are restraining widespread adoption in emerging markets.

The exorbitant costs associated with the inhalation of nitric oxide treatment, and the special delivery equipment required for the process, continues to be a major constraint in the Inhaled Nitric Oxide Market. The necessity for sophisticated ventilator technology, specially trained personnel, and consistent provision of gases makes the procedure expensive and less accessible by small and mid-size hospitals and healthcare facilities due to budget restrictions. Reimbursement problems, coupled with higher costs of operations, reduce the possibility of implementation and utilization of the therapy, especially in the developing world.

Inhaled Nitric Oxide Market Opportunities:

• Expansion of portable and next-generation nitric oxide delivery technologies presents significant market growth opportunities.

Innovations in smaller, tankless, and portable inhaled nitric oxide delivery devices are providing immense opportunities in the Inhaled Nitric Oxide Market. The growing use of such advanced technologies in hospitals enables effective delivery beyond the confines of ICU, such as during transport care and even at home. Companies launching affordable, user-friendly, and integrated inhalation delivery devices with built-in monitoring technology will be able to tap into this trend. Continuous improvements in miniaturized and digital technology, and safety upgrades, will fuel wider acceptance among patients.

More than 41% of health facilities invested in advanced portable nitric oxide delivery devices in 2025.

Inhaled Nitric Oxide Market Segmentation Analysis:

• By Product Type, Inhaled Nitric Oxide Gas (Therapeutics) held the largest market share of 72.25% in 2025, while Delivery Systems (Ventilator-Integrated Systems, Portable Systems) are expected to grow at the fastest CAGR of 9.12% during 2026–2035.

• By Application, Neonatal Hypoxic Respiratory Failure (NHRF) dominated with a 57.25% market share in 2025, whereas Chronic Obstructive Pulmonary Disease (COPD) is projected to record the fastest CAGR of 7.62% through 2026–2035.

• By Age Group, Neonates accounted for the highest market share of 65.25% in 2025, while Adults are expected to grow at the fastest CAGR of 7.62% during the forecast period.

• By End User, Hospitals held the largest share of 52.12% in 2025, while Home Care Settings are expected to grow at the fastest CAGR of 8.25% during the forecast period.

• By Distribution Channel, Direct Sales (Manufacturers to Hospitals) accounted for the highest market share of 68.23% in 2025, while Distributors & Third-Party Suppliers are expected to grow at the fastest CAGR of 6.80% during the forecast period.

By Product Type, Inhaled Nitric Oxide Gas (Therapeutics) Dominates While Delivery Systems Grow Rapidly:

Inhaled Nitric Oxide Gas (Therapeutics) segment dominated segment, based on the proven clinical effectiveness of nitric oxide in enhancing oxygenation and its extensive use in the neonatal intensive care units and in critical care applications. In 2025, the therapy saw more than 1.0 million applications in the market.

Delivery Systems are the fastest-growing segment due to rising demand for flexible and safe systems, and the need for portability in the delivery process. Over 350,000 delivery systems were adopted in 2025, mainly in advanced hospitals and in transport care facilities.

By Application, Neonatal Hypoxic Respiratory Failure (NHRF) Dominates While Chronic Obstructive Pulmonary Disease (COPD) Grows Rapidly:

The Neonatal Hypoxic Respiratory Failure (NHRF) segment dominates as a major market player, being extensively utilized for treating neonates through inhaled nitric oxide as an effective therapy. In 2025, more than 900 thousand neonates underwent treatment via inhaled nitric oxide, underscoring the extensive dependence on the therapy in the critical care of newborns.

Chronic Obstructive Pulmonary Disease (COPD) is the fastest-growing segment it has been witnessing rapid growth driven by extensive research and increasing off-label application in adults. The use of inhaled nitric oxide exceeded 120 thousand patients in 2025, especially in severe respiratory illnesses.

By Age Group, Neonates Dominate While Adults Grow Rapidly:

Neonates segment dominated the market due to the high prevalence of respiratory distress conditions in newborns and the established role of inhaled nitric oxide in neonatal care protocols. In 2025, more than 1.0 million neonatal patients received treatment, demonstrating strong and consistent demand across NICUs.

Adults are the fastest-growing segment, driven by increasing use in pulmonary hypertension and acute respiratory distress syndrome management. Treatment adoption surpassed 150 thousand adult cases in 2025, supported by expanding clinical studies and broader acceptance in critical care practice.

By End User, Hospitals Dominate While Home Care Settings Grow Rapidly:

Hospitals segment dominated the market, representing the key care facility for administering inhaled nitric oxide treatment, especially within neonatal intensive care units and intensive care facilities. More than 1.2 million inhaled nitric oxide treatments were administered through hospitals in 2025, underlining the importance of well-developed infrastructural facilities and trained staff.

Home Care Settings are the fastest-growing segment it experienced the highest growth rate due to rising usage of easily portable nitric oxide treatment systems, facilitating treatment even outside hospital premises. Over 180 thousand cases were treated using these products in 2025 within home and ambulatory care settings.

By Distribution Channel, Direct Sales Dominate While Distributors & Third-Party Suppliers Grow Rapidly:

The Direct Sales (From Manufacturers To Hospitals) segment had the highest market share as hospitals and major healthcare organizations favored direct purchasing of inhaled nitric oxide and its delivery mechanisms in order to guarantee continuous supply. The number of direct sales-based supply contracts was expected to exceed 1.3 million in 2025, demonstrating positive business dynamics between manufacturers and healthcare organizations.

The Distributors & Third-Party Suppliers segment exhibited the highest rate of growth due to increased distribution channels to medium hospitals and emerging healthcare regions. In 2025, the number of supplies via distributors was projected to be greater than 400 thousand units.

Inhaled Nitric Oxide Market Regional Analysis:

North America Inhaled Nitric Oxide Market Insights:

The North America Inhaled Nitric Oxide Market is dominant, holding a 42.84% share in 2025, attributable to a highly advanced neonatal care system and availability of critical care facilities in the U.S. and Canada. The availability of inhaled nitric oxide treatment in NICUs and hospitals ensures steady demand for the therapy. Increasing instances of neonatal hypoxic respiratory failure and pulmonary hypertension and increasing integration of delivery systems add to the growth of the market. Advancements in technology, presence of major players in the market, and favorable reimbursement models are the other factors contributing to the dominance of North America in the mature market.

U.S. Inhaled Nitric Oxide Market Insights:

The factors that contribute to the U.S. Inhaled Nitric Oxide Market include a high number of neonatal ICU admissions, well-developed healthcare facilities, and widespread adoption of nitric oxide treatments. The growth of respiratory ailments, increasing usage of advanced delivery systems, and expertise in providing such treatments lead to widespread adoption of inhaled nitric oxide treatments. Investments in neonatal care, availability of experts in the field, and innovations in technology are some of the other factors boosting the market.

Asia-Pacific Inhaled Nitric Oxide Market Insights:

Asia-Pacific's Inhaled Nitric Oxide Market is fastest Growing Region, with a projected (CAGR) of 9.17% from 2026 to 2035. This surge is fueled by enhancements in healthcare infrastructure and a growing need for sophisticated respiratory care in China, India, Japan, and Southeast Asia. The rising number of neonatal births, the proliferation of hospital networks, and increased awareness of inhaled nitric oxide therapy are all contributing to this trend. Furthermore, investments in critical care facilities, the gradual rollout of affordable delivery systems, and broader access to neonatal intensive care units are propelling substantial market growth, presenting considerable opportunities within developing economies.

China Inhaled Nitric Oxide Market Insights:

The China Inhaled Nitric Oxide Market is influenced by growing number of newborns, rising prevalence of respiratory distress diseases, and fast development of the hospital infrastructure and NICU services. Increasing use of inhaled nitric oxide treatment in tertiary hospitals, and growing availability of state-of-the-art equipment for respiratory support, contributes to increased adoption. Investments into healthcare system development, growth of the number of specialized intensive care units, and high prevalence of cost-effective technologies make China one of the key players in Asia Pacific inhaled nitric oxide mark

 Europe Inhaled Nitric Oxide Market Insights:

The Europe Inhaled Nitric Oxide Market is fueled by highly developed healthcare systems, high neonatal care standards, and rising interest to new therapeutic options. Markets such as Germany, France, and the UK have been boosting regional sales due to regular use of inhaled nitric oxide treatment in specialized wards. Expansion of hospital networks, patient safety requirements, and use of innovative delivery methods make Europe one of the leading markets in the inhaled nitric oxide segment.

Germany Inhaled Nitric Oxide Market Insights:

Germany represents a key market within Europe, driven by its advanced healthcare infrastructure and strong emphasis on neonatal and critical care services. Growth is supported by widespread use of inhaled nitric oxide therapy in hospitals, increasing focus on respiratory care management, and availability of modern medical technologies. Investments in hospital facilities, clinician training, and adherence to strict safety and treatment standards continue to strengthen Germany’s position in the regional market.

Latin America Inhaled Nitric Oxide Market Insights:

The Latin America Inhaled Nitric Oxide Market is expanding due to improving healthcare infrastructure and increasing demand for advanced neonatal and respiratory care. Adoption is supported by rising utilization of inhaled nitric oxide therapy across Brazil, Mexico, and Argentina, with ongoing investments in hospital capacity and critical care services driving growth. Gradual improvements in access to treatment, along with expanding awareness of respiratory therapies, are contributing to regional market development.

Middle East and Africa Inhaled Nitric Oxide Market Insights:

The Middle East & Africa Inhaled Nitric Oxide Market is growing due to increasing investments in healthcare infrastructure and rising demand for advanced respiratory care solutions. Expanding use of inhaled nitric oxide therapy in hospitals and critical care units is driving adoption, with countries such as Saudi Arabia, the UAE, and South Africa emerging as key markets. Development of hospital networks, improving access to neonatal care, and gradual adoption of modern delivery systems are supporting market expansion across the region.

Inhaled Nitric Oxide Market Competitive Landscape:

Mallinckrodt Pharmaceuticals plc holds a prominent position in the inhaled nitric oxide market, primarily through its INOmax therapy. This treatment is a mainstay for neonatal hypoxic respiratory failure. The company's integrated approach, which includes nitric oxide gas alongside its own delivery and monitoring systems, has solidified its influence in hospitals and NICUs. Mallinckrodt's commitment to lifecycle management, regulatory adherence, and its extensive distribution network helps maintain its market dominance. Ongoing investment in clinical research and the exploration of new therapeutic uses strengthen its competitive position in the inhaled nitric oxide market.

• In September 2025, Mallinckrodt announced continued advancements in clinical studies exploring expanded applications of inhaled nitric oxide therapy, aiming to improve patient outcomes and strengthen its leadership in neonatal and critical care markets.

Linde plc, a leader in industrial gases and engineering, plays a major part in the inhaled nitric oxide market. This is largely due to its established medical gas supply and delivery network. The company supplies hospitals and healthcare providers with high-purity nitric oxide, coupled with sophisticated gas handling and distribution systems. Linde's broad reach, coupled with its robust logistics and commitment to safety and dependability, solidifies its position as a vital supplier in critical care settings. Furthermore, Linde's continued investment in healthcare solutions, digital gas monitoring, and supply chain refinement bolsters its strong market presence.

• In July 2025, Linde enhanced its healthcare segment by expanding medical gas supply networks and investing in advanced gas delivery and monitoring technologies to support critical care applications, including inhaled nitric oxide therapy.

Air Liquide Healthcare is a major provider of medical gases and respiratory care solutions, playing a crucial role in the inhaled nitric oxide market through its comprehensive portfolio of gas supply and delivery services. The company focuses on integrating medical gases with digital health solutions and respiratory support systems to improve patient care. Its strong presence in hospitals and home healthcare, along with continuous innovation in gas delivery technologies, supports widespread adoption. Strategic partnerships, investments in healthcare infrastructure, and emphasis on patient-centric solutions reinforce Air Liquide’s competitive position.

• In October 2025, Air Liquide Healthcare expanded its respiratory care portfolio by advancing integrated gas delivery systems and digital monitoring capabilities, enhancing the efficiency and safety of inhaled nitric oxide therapy across hospital and home care settings.

Inhaled Nitric Oxide Market Key Players:

Some of the Inhaled Nitric Oxide Market Companies are: 

• Mallinckrodt Pharmaceuticals plc

• Linde plc

• Air Liquide Healthcare

• Vero Biotech LLC

• Beyond Air Inc.

• Bellerophon Therapeutics Inc.

• International Biomedical Ltd.

• Getinge AB

• SLE Ltd.

• Praxair Inc. (Linde Group)

• BOC Healthcare

• Airgas Inc.

• Matheson Tri-Gas Inc.

• NU-MED Plus Inc.

• Circassia Pharmaceuticals plc

• Hamilton Medical AG

• GE Healthcare

• Philips Respironics

• Baxter International Inc.

• Merck KGaA

• SOL Group (SOL S.p.A.)